Skip to content

Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery

A Randomized, Double-blinded Trial Comparing the Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02655653
Enrollment
114
Registered
2016-01-14
Start date
2008-10-31
Completion date
2015-10-31
Last updated
2020-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding

Brief summary

The investigators primary objective is to compare the effectiveness of epsilon-aminocaproic acid (EACA) and tranexamic acid (TA) in reducing bleeding and transfusion in cardiac surgery, with the hypothesis that TA is more effective. The investigators also seek to further examine the clinical benefits and adverse effects profiles of epsilon-aminocaproic acid and tranexamic acid.

Detailed description

This is a single center double blinded randomized controlled study comparing the effectiveness of epsilon-aminocaproic acid (EACA) and tranexamic acid (TA) in reducing 24hour blood transfusion and chest tube drainage. From October 2008 to September 2011, patients greater than 18 years of age, scheduled for cardiac surgery requiring CPB were consented. Eligible operations included; coronary artery bypass graft surgery (CABG), a heart valve repair/replacement, or a concomitant CABG and valve surgery were enrolled. Consented patients were randomized into one of the two groups using a 1:1 randomization sequence generated by a computer program. Randomization sequence and the study drugs were kept in a locked box and were opened only by unblinded study personnel who were not involved in the clinical care of the patient. This person prepared the study drug following the instructions of the study protocol, resulting in preparations of EACA and TA that contained equi-potent similar volumes of the drug in the syringe, in order to ensure blinding. Antifibrinolytic study drug was administered following anesthetic induction. EACA was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. TA was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in the investigators hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin. The primary endpoint was the amount of chest tube drainage and the amount of blood products used in the first 24 hours following surgery (surrogate measurement for blood loss) was measured at 4, 8, 12 and 24 hours after surgery. The incidence of packed red blood cells (PRBC), fresh frozen plasma (FFP), cryoprecipitate and platelets administered during the first 24 hours after surgery was collected. Additionally, patients were monitored for any complications during their stay in the hospital and up to 30 days post-operatively. Complications included renal dysfunction (defined as the need for at least 1 hemodialysis or doubling of pre-surgical creatinine levels), stroke and seizures (clinically diagnosed), myocardial infarction (new Q waves in two electrocardiogram leads), cardiac arrest, respiratory failure, re-operation and death. Monitoring of the patients prior to discharge involved chart review during their stay in the hospital; if a post-operative complication was suspected, the complication was confirmed using Montefiore Medical Center's Carecast Database, which contained independent results such as MRI's, CT scans, or labs. Additionally, computer records of the patients were searched to determine if there were documented complications in the 30-day post-operative time period.

Interventions

DRUGEpsilon-aminocaproic acid administered

Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.

DRUGTranexamic Acid administered

Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.

Sponsors

Montefiore Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Informed consent obtained before any trial-related activities * Subjects scheduled to undergo cardiac surgery requiring cardiopulmonary bypass

Exclusion criteria

* Vulnerable patient populations (unable to consent) * Religious or other prohibitive reason for not receiving blood transfusion * History of allergy to epsilon-aminocaproic acid or tranexamic acid * Pregnant or breast-feeding (if applicable) * The participation in another clinical or device trial that would affect the patient's coagulation profile * Cardiac or cardiopulmonary transplantation procedure * Any history of stroke and/or non-coronary thrombotic disorders (DVT, PE) * Clinical signs consistent with non-coronary thrombotic disease * Known congenital deficiency of Protein C, Protein S, Antithrombin and homozygous Factor V Leiden * Known congenital bleeding disorders * Weight \< 50 kg * Weight \> 150 kg * Acute renal failure or creatinine \> 2.0 mg/dL * Current surgery including any implantable ventricular assist device requiring CPB including ECMO (extracorpeal membrane oxygenation) * Current surgery including the aortic arch and/or descending thoracic aorta * Any changes to the planned surgery, which result int he patient not requiring CPB or meeting

Design outcomes

Primary

MeasureTime frameDescription
Chest Tube Drainage4 hours, 8 hours, 12 hours, 24 hoursChest tube drainage are collected from the nursing records, every 4th hourly the amount fluid collected is reported in the collection sheets.
Median Amount of Blood Products Used24 hours after surgeryFour types of blood products may be given through blood transfusions: whole blood, red blood cells, platelets, and plasma

Secondary

MeasureTime frameDescription
Diagnosis of Myocardial Infarction Post-operationWithin 30 days after surgeryConfirmed diagnosis of myocardial infraction and hospitalization for the same within 30 days after the surgery
Number of Participants Who Have Confirmed Diagnosis of Respiratory ArrestWithin 30 days after surgeryConfirmed diagnosis of respiratory arrest and hospitalization for the same within 30 days after the surgery
Number of Participants With Confirmed Diagnosis of StrokeWithin 30 days after surgeryConfirmed diagnosis of stroke and hospitalization for the same within 30 days after the surgery
Diagnosis of Renal Dysfunction Post-operationWithin 30 days after surgeryConfirmed diagnosis of renal dysfunction and hospitalization for the same within 30 days after the surgery
Number of Participants With Confirmed Diagnosis of SeizureWithin 30 days after surgeryConfirmed diagnosis of seizure and hospitalization for the same within 30 days after the surgery
ReoperationWithin 30 days after surgeryConfirmed diagnosis of reopeartion and hospitalization for the same within 30 days after the surgery
Mortality Within 30 Days Post-operationWithin 30 days after surgery

Other

MeasureTime frameDescription
Patient DemographicsBaselineMeasurements taken as a composite. BMI, Sex, Age are to be determined to ensure that the subjects' characteristics were comparable between the Epsilon-aminocaproic Acid and Tranexamic Acid groups.
Type of SurgeryIntraoperative
Intraoperative CharacteristicsIntraoperativeMeasurements are taken as a composite to determine that the subjects' characteristics are comparable between the Epsilon-aminocaproic Acid and Tranexamic Acid groups. Measurements include temperature, Heparin dose, protamine given, time of surgery, time of cardiopulmonary bypass, and aortic clamp time.

Participant flow

Participants by arm

ArmCount
Epsilon-aminocaproic Acid (EACA)
Epsilon-aminocaproic acid administered following anesthetic induction: EACA was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Epsilon-aminocaproic acid administered: Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
56
Tranexamic Acid (TA)
Tranexamic Acid administered following induction: TA was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Tranexamic Acid administered: Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
58
Total114

Baseline characteristics

CharacteristicEpsilon-aminocaproic Acid (EACA)Tranexamic Acid (TA)Total
Age, Continuous64 years65 years64 years
Region of Enrollment
United States
56 Participants58 Participants114 Participants
Sex/Gender, Customized
Female
19 Participants28 Participants47 Participants
Sex/Gender, Customized
Male
37 Participants30 Participants67 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
1 / 561 / 58
other
Total, other adverse events
0 / 560 / 58
serious
Total, serious adverse events
20 / 5614 / 58

Outcome results

Primary

Chest Tube Drainage

Chest tube drainage are collected from the nursing records, every 4th hourly the amount fluid collected is reported in the collection sheets.

Time frame: 4 hours, 8 hours, 12 hours, 24 hours

ArmMeasureGroupValue (MEAN)Dispersion
Epsilon-aminocaproic Acid (EACA)Chest Tube Drainage4 hr200 mLStandard Deviation 375
Epsilon-aminocaproic Acid (EACA)Chest Tube Drainage8 hr375 mLStandard Deviation 550
Epsilon-aminocaproic Acid (EACA)Chest Tube Drainage12 hr425 mLStandard Deviation 750
Epsilon-aminocaproic Acid (EACA)Chest Tube Drainage24 hr700 mLStandard Deviation 1100
Tranexamic Acid (TA)Chest Tube Drainage8 hr400 mLStandard Deviation 675
Tranexamic Acid (TA)Chest Tube Drainage24 hr800 mLStandard Deviation 1225
Tranexamic Acid (TA)Chest Tube Drainage4 hr225 mLStandard Deviation 400
Tranexamic Acid (TA)Chest Tube Drainage12 hr500 mLStandard Deviation 825
Primary

Median Amount of Blood Products Used

Four types of blood products may be given through blood transfusions: whole blood, red blood cells, platelets, and plasma

Time frame: 24 hours after surgery

ArmMeasureValue (MEDIAN)Dispersion
Epsilon-aminocaproic Acid (EACA)Median Amount of Blood Products Used.59 LStandard Deviation 1.3
Tranexamic Acid (TA)Median Amount of Blood Products Used1.20 LStandard Deviation 2.2
Secondary

Diagnosis of Myocardial Infarction Post-operation

Confirmed diagnosis of myocardial infraction and hospitalization for the same within 30 days after the surgery

Time frame: Within 30 days after surgery

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Epsilon-aminocaproic Acid (EACA)Diagnosis of Myocardial Infarction Post-operation1 Participants
Tranexamic Acid (TA)Diagnosis of Myocardial Infarction Post-operation1 Participants
Secondary

Diagnosis of Renal Dysfunction Post-operation

Confirmed diagnosis of renal dysfunction and hospitalization for the same within 30 days after the surgery

Time frame: Within 30 days after surgery

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Epsilon-aminocaproic Acid (EACA)Diagnosis of Renal Dysfunction Post-operation3 Participants
Tranexamic Acid (TA)Diagnosis of Renal Dysfunction Post-operation2 Participants
Secondary

Mortality Within 30 Days Post-operation

Time frame: Within 30 days after surgery

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Epsilon-aminocaproic Acid (EACA)Mortality Within 30 Days Post-operation1 Participants
Tranexamic Acid (TA)Mortality Within 30 Days Post-operation1 Participants
Secondary

Number of Participants Who Have Confirmed Diagnosis of Respiratory Arrest

Confirmed diagnosis of respiratory arrest and hospitalization for the same within 30 days after the surgery

Time frame: Within 30 days after surgery

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Epsilon-aminocaproic Acid (EACA)Number of Participants Who Have Confirmed Diagnosis of Respiratory Arrest11 Participants
Tranexamic Acid (TA)Number of Participants Who Have Confirmed Diagnosis of Respiratory Arrest5 Participants
Secondary

Number of Participants With Confirmed Diagnosis of Seizure

Confirmed diagnosis of seizure and hospitalization for the same within 30 days after the surgery

Time frame: Within 30 days after surgery

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Epsilon-aminocaproic Acid (EACA)Number of Participants With Confirmed Diagnosis of Seizure0 Participants
Tranexamic Acid (TA)Number of Participants With Confirmed Diagnosis of Seizure0 Participants
Secondary

Number of Participants With Confirmed Diagnosis of Stroke

Confirmed diagnosis of stroke and hospitalization for the same within 30 days after the surgery

Time frame: Within 30 days after surgery

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Epsilon-aminocaproic Acid (EACA)Number of Participants With Confirmed Diagnosis of Stroke2 Participants
Tranexamic Acid (TA)Number of Participants With Confirmed Diagnosis of Stroke2 Participants
Secondary

Reoperation

Confirmed diagnosis of reopeartion and hospitalization for the same within 30 days after the surgery

Time frame: Within 30 days after surgery

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Epsilon-aminocaproic Acid (EACA)Reoperation3 Participants
Tranexamic Acid (TA)Reoperation4 Participants
Other Pre-specified

Intraoperative Characteristics

Measurements are taken as a composite to determine that the subjects' characteristics are comparable between the Epsilon-aminocaproic Acid and Tranexamic Acid groups. Measurements include temperature, Heparin dose, protamine given, time of surgery, time of cardiopulmonary bypass, and aortic clamp time.

Time frame: Intraoperative

Other Pre-specified

Patient Demographics

Measurements taken as a composite. BMI, Sex, Age are to be determined to ensure that the subjects' characteristics were comparable between the Epsilon-aminocaproic Acid and Tranexamic Acid groups.

Time frame: Baseline

Other Pre-specified

Type of Surgery

Time frame: Intraoperative

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026